Accunovo Biotechnologies

Accunovo Biotechnologies is a pre-clinical stage biotechnology company specializing in molecular imaging and targeted radiotheranostics for oncology. Based in Chapel Hill, North Carolina, the company is developing novel targeted PET imaging probes and therapeutic agents by combining unique biomarker-binding molecules with precision radiopharmaceuticals. Its primary focus is on developing theranostic agents targeting neurotensin receptor 1 (NTSR1) for the complementary management of prostate cancer, particularly for patients who lack PSMA expression or do not respond to PSMA-based treatments. Accunovo's proprietary technology utilizes multiamine macrocyclic moieties as linkers or chelators to achieve elevated tumor uptake, minimal background interference, and prolonged tumor retention.